ASHP believes Mevacor is not safe to go over the counter but might be appropriate for behind the counter.
When FDA meets on Dec. 13 to consider whether Mevacor (lovastatin, Merck) should go over the counter, one organization the agency can expect to oppose the measure is ASHP. In a letter to the FDA explaining its position, ASHP said it believes it's not safe for Mevacor to switch to OTC status. Instead, ASHP advised, moving it to a behind-the-counter category should be considered.
To see more Daily News articles, click here.
To go to the Drug Topics homepage, click here.